REL RELX PLC
RELX PLC, together with its subsidiaries, provides information-based analytics and decision tools for professional and business customers in North America, Europe, and internationally. It operates through four segments: Risk; Scientific, Technical & Medical; Legal; and Exhibitions. The Risk segment offers information-based analytics and decision tools that combine public and industry specific content with technology and algorithms to assist clients in evaluating and predicting risk, as well as a portfolio of commercial healthcare products. Its Scientific, Technical & Medical segment provides scientific and medical information and data sets for science and healthcare. The Legal segment provides legal, regulatory, and business information and analytics. Its Exhibitions segment combines digital tools and data to help customers connect in-person and online, discover new markets, source products, generate leads, and transact. The company was formerly known as Reed Elsevier PLC and changed its name to RELX PLC in July 2015. RELX PLC was incorporated in 1903 and is headquartered in London, the United Kingdom.…
Industry Peers
Specialty Business ServicesKey Statistics
About RELX (LON: REL)
›
RELX (LON: REL) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Specialty Business Services industry, part of the Industrials sector, and reports about 37,000 employees.
The shares were at 2963.00 GBp on 19 November 2026, down 5.5% over 52 weeks. Its 52-week range is 1991.00 GBp to 3448.50 GBp: the price is 14.1% below the high and 48.8% above the low.
At a market capitalisation of 51.38B GBP, it trades at 23.7 times trailing earnings and 18.8 times forward earnings. The median trailing P/E of its 18 largest Specialty Business Services peers is 30.3, a discount of 22% for REL. It pays a dividend yielding 2.32% (it pays out 54% of its earnings), against a median of 1.81% among the dividend payers in that peer group.
RELX reports return on equity of 87.3%, an operating margin of 31.7% and revenue up 2.7% year over year.
Its debt exceeds its cash by 8.69B GBP, a debt-to-equity ratio of 3.07. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Buy; their mean price target of 3509.12 GBp is 18.4% above the current price. The next earnings report is expected on 11 February 2027.